Adults 18 to 130, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression Free SurvivalPrimary· Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.
Group
Value
95% CI
Cediranib 20 mg
9.9
6.3 – 13.5
Bevacizumab 5 mg/kg
10.3
6.5 – 14.1
Overall SurvivalSecondary· Randomisation until data cut-off
Number of months from randomisation to the date of death from any cause
Group
Value
95% CI
Cediranib 20 mg
22.8
13.3 – 32.3
Bevacizumab 5 mg/kg
21.3
12.2 – 32.8
Objective Response RateSecondary· Up until data cut-off
Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:
CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs.
Group
Value
95% CI
Cediranib 20 mg
328
Bevacizumab 5 mg/kg
337
Duration of ResponseSecondary· Up until data cut-off date of 15/11/2007
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009.
Group
Value
95% CI
Cediranib 20 mg
8.6
6.1 – 12.1
Bevacizumab 5 mg/kg
9.6
6.5 – 13.6
Percentage Change in Tumour SizeSecondary· Baseline to Week 8
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)\*100
Group
Value
95% CI
Cediranib 20 mg
-23.2
± 21.8
Bevacizumab 5 mg/kg
-22.1
± 19.55
Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)Secondary· Baseline through to data cut-off
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded.
Group
Value
95% CI
Cediranib 20 mg
170
56 – 328
Bevacizumab 5 mg/kg
245
112 – 348
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04090567 — Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
· Phase 2
· recruiting
NCT03741426 — WIRE - Novel Treatments in Renal Cell Cancer
· Phase 2
· unknown
NCT03851614 — Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
· Phase 2
· active not recruiting
NCT03570437 — Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
· Phase 2
· unknown
NCT02899728 — Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
· Phase 2
· terminated
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
· Phase 1, PHASE2
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes
· recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes
· recruiting
Other AstraZeneca trials
Trials by the same sponsor.
NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
· not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential
· not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
· NA
· not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
· Phase 4
· not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 14 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00384176.